NCT04931342 2026-03-10
BOUQUET
Hoffmann-La Roche
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT02675829 2026-03-04
Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04266249 2026-03-02
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT07421141 2026-02-27
Opti-HER2
National Medical Research Radiological Centre of the Ministry of Health of Russia
Phase 2 Active not recruiting
NCT03587740 2026-02-17
ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT00781612 2025-12-24
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Genentech, Inc.
Phase 2 Active not recruiting
NCT04439110 2025-11-21
Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04733118 2025-11-20
PHERGAIN-2
MedSIR
Phase 2 Active not recruiting
NCT02314481 2025-05-23
DARWINII
University College, London
Phase 2 Active not recruiting
NCT02326974 2025-03-05
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Dana-Farber Cancer Institute
Phase 2 Active not recruiting